RenovoRx, Inc.
RNXT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001574094
No open-market purchases or sales by RenovoRx, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $9.00M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding RenovoRx, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 12 | 9 | −3 |
| Shares | 2.19M | 244.3K | −1.94M (−88.8%) |
| Value | $9.64M | $552.2K | −$9.08M (−94.3%) |
New holders (1)
Institutions that held RenovoRx, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 12,363 | $27.9K | 0.00% |
Sold out (4)
Institutions that held RenovoRx, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Bank of Montreal | 975,000 | $5.41M |
| Armistice Capital, LLC | 982,921 | $3.43M |
| Cambridge Investment Research Advisors, Inc. | 14,900 | $52.0K |
| UBS Group AG | 2,530 | $8.82K |